Enzon Pharmaceuticals (Enzon Pharmaceuticals) Total Inventories : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Total Inventories?

Enzon Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Enzon Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Enzon Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.03.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Enzon Pharmaceuticals Total Inventories Historical Data

The historical data trend for Enzon Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Total Inventories Chart

Enzon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

Enzon Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Enzon Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Enzon Pharmaceuticals (OTCPK:ENZN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Enzon Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(45.988	+	0.75 * 0	+	0.5 * 0	-	43.535
-	0	-	0)	/	74.2146
=	0.03

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Enzon Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Enzon Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Enzon Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Enzon Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

EZ1:Germany

Address

20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016

Website

http://www.enzon.com

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.

Executives

Randolph C Read	director	C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone	director	C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick	director	C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper	other: See explanation of responses	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc	other: See explanation of responses	2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper	other: See explanation of responses	6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc.	other: See Footnote 1	600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp.	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman	10 percent owner, other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn	10 percent owner	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein	officer: VP-Finance and PFO
Jonathan Christodoro	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121